Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482251 | 0.85 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5600844 | 0.85 | CRHR1 (1.00) | CRHR1 | |
| Hydrochloric Acid SCHEMBL5872497 | 0.84 | CRHR1 (0.98) | CRHR1 | |
| Hydrochloric Acid SCHEMBL29601420 | 0.84 | CRHR1 (0.98) | CRHR1 | |
| SCHEMBL5599550 | 0.81 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL5872485 | 0.80 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL5872490 | 0.80 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL23460066 | 0.79 | CRHR1 (0.90) | CRHR1 | |
| SCHEMBL29983280 | 0.78 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL23459887 | 0.78 | CRHR1 (0.80) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0880523-B1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-08-16 | — | — | EP | claimed |
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-01 | — | — | US | claimed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. | 2003-07-03 | — | — | US | claimed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | claimed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | claimed |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-6777404-B2 | SUCH AS 3-((4-METHYL-BENZYL)-(3,6-DIMETHYL-1-(2,4,6-TRIMETHYLPHENYL)-1H-PYRAZOLO -(3,4-D)PYRIMIDIN-4-YL)-AMINO)PROP AN-1-OL FOR TREATING/PREVENTING SYNDROME X; KITS | PFIZER INC | 2004-08-17 | — | — | US | disclosed |
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | PFIZER INC | 2004-04-29 | — | — | US | disclosed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885 |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | CRHR1 3/4885 |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, OPRL1 | CRHR1 1/4885 |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | CRH, CRHR2, CRHR1 | CRHR1 3/4885 |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | HTR2B, HTR1B, HTR3B | CRHR1 16/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
| US-20040082597-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.